Genzyme Corp. may be able to grow replacement cartilage for your knee from a few of your cells, but it hasn't figured out a way to grow money in the lab-yet. For now, it must rely on David J. McLachlan to raise cash from banks and investors.

As chief financial officer of Genzyme, one of the world's five largest biotech firms, Mr. McLachlan leads it and its subsidiaries through the volatile world of biotech finance. His latest feat: securing a $225 million syndicated loan last December from Fleet Financial Corp. and Bank of Boston Corp.

Limited Time Offer

Save $400 off your subscription. Special offer ends April 30, 2017.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.